CTP-730: Phase I started

Concert began a double-blind, placebo-controlled, Australian Phase I trial to evaluate single doses of 5, 10, 20, 30 and 40 mg oral CTP-730 in up to 40 healthy volunteers. Concert and Celgene are partnered to develop deuterium-modified compounds for cancer and inflammation. The deal is initially focusing on CTP-730 but may include up to 4 programs. Concert granted Celgene an exclusive, worldwide license to develop and commercialize CTP-730 (see BioCentury, May 13, 2013). ...